ALN-TTR01
ALN-TTR01-001
Phase 1 small_molecule completed
Quick answer
ALN-TTR01 for Transthyretin Mediated Amyloidosis (ATTR) is a Phase 1 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Transthyretin Mediated Amyloidosis (ATTR)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed